Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Retained Earnings (2022 - 2025)

Historic Retained Earnings for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to -$683.4 million.

  • Taysha Gene Therapies' Retained Earnings fell 1712.52% to -$683.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$683.4 million, marking a year-over-year decrease of 1712.52%. This contributed to the annual value of -$602.3 million for FY2024, which is 1740.68% down from last year.
  • Taysha Gene Therapies' Retained Earnings amounted to -$683.4 million in Q3 2025, which was down 1712.52% from -$650.7 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Retained Earnings ranged from a high of -$285.8 million in Q1 2022 and a low of -$683.4 million during Q3 2025
  • Over the past 4 years, Taysha Gene Therapies' median Retained Earnings value was -$537.1 million (recorded in 2024), while the average stood at -$501.9 million.
  • As far as peak fluctuations go, Taysha Gene Therapies' Retained Earnings plummeted by 6209.4% in 2023, and later crashed by 406.1% in 2024.
  • Taysha Gene Therapies' Retained Earnings (Quarter) stood at -$401.4 million in 2022, then decreased by 27.79% to -$513.0 million in 2023, then decreased by 17.41% to -$602.3 million in 2024, then dropped by 13.47% to -$683.4 million in 2025.
  • Its Retained Earnings stands at -$683.4 million for Q3 2025, versus -$650.7 million for Q2 2025 and -$623.8 million for Q1 2025.